EirGenix Inc. (TPE:6589)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
63.40
-0.10 (-0.16%)
At close: Dec 22, 2025
-11.58%
Market Cap19.16B
Revenue (ttm)936.18M
Net Income (ttm)-705.76M
Shares Out302.20M
EPS (ttm)-2.33
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume328,498
Average Volume981,950
Open63.80
Previous Close63.50
Day's Range63.30 - 63.80
52-Week Range52.70 - 84.30
Beta0.55
RSI30.95
Earnings DateMar 18, 2026

About EirGenix

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and curr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 207
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6589
Full Company Profile

Financial Performance

In 2024, EirGenix's revenue was 1.01 billion, a decrease of -1.34% compared to the previous year's 1.02 billion. Losses were -698.34 million, -23.70% less than in 2023.

Financial Statements

News

There is no news available yet.